Literature DB >> 26286102

CSF N-glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorder.

Rita Barone1, Luisella Sturiale2, Agata Fiumara3, Angelo Palmigiano2, Rosaria O Bua2, Renata Rizzo1, Mario Zappia4, Domenico Garozzo2.   

Abstract

Protein N-glycosylation consists in the synthesis and processing of the oligosaccharide moiety (N-glycan) linked to a protein and it serves several functions for the proper central nervous system (CNS) development and function. Previous experimental and clinical studies have shown the importance of proper glycoprotein sialylation for the synaptic function and the occurrence of autism spectrum disorders (ASD) in the presence of sialylation deficiency in the CNS. Late-onset Tay Sachs disease (LOTSD) is a lysosomal disorder caused by mutations in the HEXA gene resulting in GM2-ganglioside storage in the CNS. It is characterized by progressive neurological impairment and high co-occurrence of psychiatric disturbances. We studied the N-glycome profile of the cerebrospinal fluid (CSF) in a 14 year-old patient with GM2-gangliosidosis (LOTSD). At the age of 4, the patient presented regressive autism fulfilling criteria for childhood disintegrative disorder (CDD). A CSF sample was obtained in the course of diagnostic work-up for the suspicion of an underlying neurodegenerative disorder. We found definite changes of CSF N-glycans due to a dramatic decrease of sialylated biantennary and triantennary structures and an increase of asialo-core fucosylated bisected N-glycans. No changes of total plasma N-glycans were found. Herein findings highlight possible relationships between the early onset psychiatric disturbance featuring CDD in the patient and defective protein sialylation in the CNS. In conclusion, the study first shows aberrant N-glycan structures of CSF proteins in LOTSD; unveils possible pathomechanisms of GM2-gangliosidosis; supports existing relationships between neuropsychiatric disorders and unproper protein glycosylation in the CNS.
© 2015 International Society for Autism Research, Wiley Periodicals, Inc.

Entities:  

Keywords:  CSF N-glycome; GM2 gangliosidosis; MALDI-TOF MS; Tay Sachs Disease; autism spectrum disorders

Mesh:

Substances:

Year:  2015        PMID: 26286102     DOI: 10.1002/aur.1541

Source DB:  PubMed          Journal:  Autism Res        ISSN: 1939-3806            Impact factor:   5.216


  6 in total

1.  A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses.

Authors:  Rita Barone; Salvatore Alaimo; Marianna Messina; Alfredo Pulvirenti; Jean Bastin; Alfredo Ferro; Richard E Frye; Renata Rizzo
Journal:  Front Psychiatry       Date:  2018-12-07       Impact factor: 4.157

2.  N-Glycan Profile of Cerebrospinal Fluids from Alzheimer's Disease Patients Using Liquid Chromatography with Mass Spectrometry.

Authors:  Byeong Gwan Cho; Lucas Veillon; Yehia Mechref
Journal:  J Proteome Res       Date:  2019-09-16       Impact factor: 4.466

3.  Comorbid Analysis of Genes Associated with Autism Spectrum Disorders Reveals Differential Evolutionary Constraints.

Authors:  Maude M David; David Enard; Alp Ozturk; Jena Daniels; Jae-Yoon Jung; Leticia Diaz-Beltran; Dennis P Wall
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

4.  Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.

Authors:  Catlyn Cavender; Linley Mangini; Jeremy L Van Vleet; Carley Corado; Emma McCullagh; Heather L Gray-Edwards; Douglas R Martin; Brett E Crawford; Roger Lawrence
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

5.  N-Glycomics of Cerebrospinal Fluid: Method Comparison.

Authors:  Byeong Gwan Cho; Cristian D Gutierrez Reyes; Yehia Mechref
Journal:  Molecules       Date:  2021-03-19       Impact factor: 4.411

6.  Childhood Disintegrative Disorder (CDD): Symptomatology of the Norwegian Patient Population and Parents' Experiences of Patient Regression.

Authors:  Martin John Ellis; Kenneth Larsen; Sophie Seychelle Havighurst
Journal:  J Autism Dev Disord       Date:  2021-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.